Global Auto-Injectors Market 2023


产品代码: GM04952R 行业: 地区:

The global auto-injectors market exhibits strong growth potential, forecast to grow at a CAGR of 13.4% 从 2022-2029 to reach a value of USD 101.8 十亿 2029. Rising prevalence of chronic conditions like rheumatoid arthritis, multiple sclerosis and anaphylaxis which require regular self-administration of medication. This drives demand for convenient auto-injector devices among patients.

Technological advancements enabling minimally invasive drug delivery, shorter needle lengths for improved comfort, and add-on monitoring tools to track dosage. Companies are innovating to enhance performance and user experience. Favorable trends like the shift towards home healthcare due to COVID-19 pandemic restrictions, and the growing geriatric population susceptible to chronic illnesses. This is increasing adoption of self-injectable devices.

然而, the preference among some patient populations for alternative delivery methods like pre-filled syringes, pens, and pumps may restrain uptake. Complex regulatory requirements also pose hurdles in new product approvals.


The market is segmented based on product type, 给药途径, therapy, 最终用户, 和地理.

Segmentation by Product Type
Disposable Autoinjectors
Reusable Autoinjectors

Segmentation by Route of Administration

Segmentation by Therapy
Multiple Sclerosis
Rheumatoid Arthritis
其他的 (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia)

Segmentation by End User
Ambulatory Care
Home Care Settings
Hospital and Clinics

北美 – 美国, 加拿大, 墨西哥
欧洲 – 英国, 德国, 法国, 意大利, 西班牙, and Rest of Europe
亚太 – 中国, 日本, 印度, 澳大利亚, 韩国, and Rest of Asia-Pacific
拉美 – 巴西, 阿根廷, and Rest of Latin America
中东和非洲 – GCC, 南非, and Rest of Middle East and Africa

Rheumatoid arthritis (RA) represents a key therapy area driving growth within the global auto-injectors market. RA is an autoimmune condition causing chronic joint inflammation and pain due to the immune system mistakenly attacking healthy tissue. It has higher prevalence among the elderly female population.

As populations age, the incidence of RA is expected to increase, along with demand for self-injectable treatments that are convenient and simple to administer. Studies demonstrate RA patients using auto-injectors have better outcomes and find the devices more comfortable versus conventional injections by caregivers.

Companies are also promoting improved user experience through design advancements like hidden needles and ergonomic shapes. Such initiatives around patient centricity and innovation are catalyzing uptake of auto-injectors for RA treatment.

地理上, North America accounts for a major share of the disposable auto-injectors market. Early adoption of new products, a steady pace of regulatory approvals and rising chronic disease prevalence make the region conducive for market growth. Specifically, the United States represents a lucrative market, aided by rapid uptake of technological advancements, new product introductions and expanding patient populations requiring self-administered drug delivery.


The Auto-Injectors market is highly competitive and includes major players like Abbvie Inc., Amgen Inc., Antares Pharma, 公司. (Halozyme Therapeutics, 公司), Becton Dickinson and Co., Eli Lilly and Company, 葛兰素史克公司, 约翰逊 & 约翰逊, 默克公司, 诺华公司, SHL Medical AG, 梯瓦制药工业有限公司, Ypsomed AG, 除其他外, who hold a significant market share.


In May 2022, Jabil Healthcare, a division of Jabil Inc., launched the Qfinity autoinjector platform, providing a cost-effective solution for subcutaneous drug self-administration.

Also in May 2022, Stevanato Group S.p.A. formed an exclusive agreement with Owen Mumford Ltd. for its Aidaptus auto-injector.


To analyze and forecast the market size of the global auto-injectors market.
To classify and forecast the global auto-injectors market based on product type, 给药途径, therapy, 最终用户, geography.
To identify drivers and challenges for the global auto-injectors market.
检查合并等竞争性发展 & 收购, 协议, 合作与伙伴关系, ETC。, in the global auto-injectors market.
To identify and analyze the profile of leading players operating in the global auto-injectors market.


Gain a reliable outlook of the global auto-injectors market forecasts from 2023 到 2029 跨场景.
Excel 格式的跨场景分析易用性的市场预估.

Global Auto-Injectors Market 2023

对这份报告感兴趣? 立即获取免费样品!
Global Auto-Injectors Market 2023 - 报告范围


市场规模 (2022)

美元 42.2 十亿





复合年增长率 (2023-2029)





产品类别, Route Of Administration, Therapy, 终端用户, 地理




Abbvie Inc., Amgen Inc., Antares Pharma Inc. (Halozyme Therapeutics Inc.), Becton Dickinson and Co., Eli Lilly and Company, 葛兰素史克公司, 约翰逊 & 约翰逊, 默克公司, 诺华公司, SHL Medical AG, 梯瓦制药工业有限公司, Ypsomed AG

本报告可以灵活地根据您的具体需求进行定制. 我们的分析师和行业专家团队将直接与您合作,全面了解您的需求.

下载免费样品 - Global Auto-Injectors Market 2023